BALA CYNWYD, Pa., May 22, 2015 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Synageva BioPharma Corp. ("Synageva" or "the Company") (Nasdaq -GEVA-News) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Alexion Pharmaceuticals, Inc. ("Alexion").

Click here to learn more about the investigation http://brodsky-smith.com/942-geva-synageva-biopharma-corp.html, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Synageva shareholders will receive only 0.6581 of an Alexion share and $115.00 in cash for each share of Synageva stock they own. The transaction values Synageva at only approximately $225.92 per share. The investigation concerns whether the Board of  Synageva breached their fiduciary duties to shareholders and whether Alexion is underpaying for Synageva. The transaction may undervalue Synageva  as the Company has  a strong pipeline of protein therapeutic programs for patients with rare diseases who have unmet medical needs. This includes Kanuma, for the treatment of Lysosomal Acid Lipase Deficiency. In addition, an analyst has placed a $230.00 per share price target on Synageva stock.

If you own shares of Synageva and wish to discuss the legal ramifications of   the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA  19004, by visiting http://brodsky-smith.com/942-geva-synageva-biopharma-corp.html, or calling toll  free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-brodsky--smith-llc-announces-investigation-of-the-board-of-directors-of-synageva-biopharma-corp--geva-300087896.html

SOURCE Brodsky & Smith, LLC

Copyright 2015 PR Newswire

(MM) (NASDAQ:GEVA)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024 Click aqui para mais gráficos (MM).
(MM) (NASDAQ:GEVA)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024 Click aqui para mais gráficos (MM).